Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Torii to Skip November Listing of Tablet-Form Pollen Allergy Therapy
October 10, 2017
- Kyowa Kirin Pulls Plug on Tivantinib, Follows Daiichi Sankyo
October 10, 2017
- Nippon Kayaku Clinches Supreme Court Victory in Elplat Patent Suit
October 6, 2017
- AZ to Transfer Migraine Med Zomig to Sawai Mid-Next Year
October 6, 2017
- Daiichi Sankyo, Osaka Univ. Spin-Off to Jointly Develop iPS Cell-Derived Cardiomyocyte Sheet, Aiming at Commercialization within 5 Years
October 6, 2017
- Sanofi Files Spiramycin for Congenital Toxoplasmosis
October 6, 2017
- Nipro Aims at 100 Billion Yen Sales for Pharma Biz by FY2020, Seeking No. 1 Spot among Research-Oriented Makers in Generic Field
October 5, 2017
- Humira Designated as Orphan Drug for Hidradenitis Suppurativa: AbbVie
October 5, 2017
- Sato, Eisai to Copromote Oral Onychomycosis Drug
October 4, 2017
- Takeda’s Oral Relugolix Scores Non-Inferiority vs Leuprorelin in Uterine Fibroids: Japan PIII
October 4, 2017
- Takeda-Backed Chromatography Startup Launched at Shonan Research Center
October 4, 2017
- Trazenta-Jardiance Combo Filed in Japan: Lilly/Boehringer
October 4, 2017
- EA Pharma, Mochida in Tie-Up Deal for 2nd Constipation Med
October 4, 2017
- Torii Named CEO of Fujifilm-Kyowa Kirin JV after Humira Biosimilar Filing
October 4, 2017
- JT and Bayer Begin Japan PIII for HIF-PH Inhibitors, Follow Astellas and GSK
October 4, 2017
- Celgene Looks to Expand Footprint in Japan Unmet Need Arena
October 4, 2017
- Japan Debut of MSD’s Zetia/Lipitor Combo Delayed as Cyberattack Woes Continue
October 4, 2017
- Shoichiro Ogawa Tapped as Alcon Pharma Japan Chief
October 3, 2017
- Olaparib Gets Orphan Status for BRCA-Mutated Breast Cancer
October 3, 2017
- Astellas to Launch 3-Way Copromotion Scheme for Kiklin
October 3, 2017
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…